Cancers with microsatellite instability (MSI)
Coordinated by Pr. Alex Duval
Cancers with instability of DNA microsatellite repeat sequences (MSI) constitute a family of frequent tumors, associated with numerous localizations (colon, stomach, endometrium, pancreas, prostate, lung, breast, ovary, brain, etc.). The main objectives of this program, dedicated to MSI cancers of all locations, are:
- Understand the processes that underlie MSI tumor initiation and progression and shape the microenvironment of these cancers.
- To develop new diagnostic tools and therapeutic regimens adapted to their modern management by precision medicine in full emergence (immunotherapy, inhibitors of immune checkpoints).
Synthesis for the general public
[ESMO 2019] Efficacy of PD-1 Inhibitors Confirmed in the Treatment of “MSI” Tumours
The pooled analysis of two studies, KEYNOTE-164 and KEYNOTE-168, in which Pr Thierry André, Head of the Digestive Oncology Department […]
Treatment of gastrointestinal MSI cancers by immuno-oncology
How to Improve the Results With IO Agents in MSI GI Cancer? https://oncologypro.esmo.org/content/download/231632/3918938/version/1/file/WORLDGI2019_76_andre.pdf
Pembrolizumab in Colorectal Cancer – Stage IV MSI-H – KEYNOTE-164 (NCT02460198)
Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164 Le DT, Kim TW, Van […]